Skip to main content

Advertisement

Springer Nature Link
Log in

Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting

  • Progress in Hematology
  • Molecular pathogenesis of leukemia and leukemia stem cells
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Acute promyelocytic leukemia (APL) is characterized by a t(15;17) translocation that yields a PML/RARA fusion protein. Expression of PML/RARA, a potent transcriptional repressor, induces APL in mice. Both retinoic acid (RA) and arsenic trioxide directly target PML/RARA-mediated transcriptional repression and protein stability, inducing rapid differentiation of the promyelocytes and clinical remission in most APL patients. RA also triggers growth arrest and progressive clearance of leukemia initiating cells (LIC), both ex vivo and in vivo. Suboptimal RA concentrations or expression of the PLZF/RARA variant allows complete RA-induced differentiation, but neither LIC clearance nor disease remission. Thus, RA-induced differentiation and LIC clearance may be uncoupled. The RA/arsenic trioxide association, which dramatically synergizes for PML/RARA degradation but not for differentiation, rapidly clears LIC in a proteasome-dependent manner, resulting in APL eradication in murine models and patients. Collectively, these results demonstrate that LIC clearance, which mirrors PML/RARA degradation, is the primary basis for APL cure by the RA/arsenic trioxide association, rather than differentiation. Oncogene degradation could be a generally applicable therapeutic strategy to clear LICs in several types of tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167–215.

    PubMed  CAS  Google Scholar 

  2. Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de Thé H. Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat Rev Cancer. 2005;5:821–7.

    Article  PubMed  CAS  Google Scholar 

  3. Bernardi R, Grisendi S, Pandolfi PP. Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene. 2002;21:3445–58.

    Article  PubMed  CAS  Google Scholar 

  4. Chen Z, Brand N, Chen A, Chen S, Tong J, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor a locus due to a variant t(11, 17) translocation in acute promyelocytic leukemia. EMBO J. 1993;12:1161–7.

    PubMed  CAS  Google Scholar 

  5. Licht JD. Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell. 2006;9:73–4.

    Article  PubMed  CAS  Google Scholar 

  6. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5:811–20.

    Article  PubMed  CAS  Google Scholar 

  7. Lin R, Evans R. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000;5:821–30.

    Article  PubMed  CAS  Google Scholar 

  8. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010;17:173–85.

    Google Scholar 

  9. Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell. 2007;12:23–35.

    Article  PubMed  CAS  Google Scholar 

  10. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 2005;7:143–53.

    Article  PubMed  CAS  Google Scholar 

  11. Kamashev DE, Vitoux D, de Thé H. PML/RARA-RXR oligomers mediate retinoid- and rexinoid-/cAMP in APL cell differentiation. J Exp Med. 2004;199:1–13.

    Article  CAS  Google Scholar 

  12. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell. 2007;11:513–25.

    Article  PubMed  CAS  Google Scholar 

  13. Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, et al. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell. 2007;12:36–51.

    Article  PubMed  CAS  Google Scholar 

  14. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, et al. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 2009;23:1195–206.

    Article  PubMed  CAS  Google Scholar 

  15. Lallemand-Breitenbach V, de Thé H. (2010) PML nuclear bodies. CSH Perspect Biol. 2010, in press.

  16. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008;453:1072–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007;8:1006–16.

    Google Scholar 

  18. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, et al. The t(15;17) translocation alters a nuclear body in a RA-reversible fashion. EMBO J. 1994;13:1073–83.

    PubMed  CAS  Google Scholar 

  19. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, et al. A novel macromolecular structure is a target of the promyelocyte—retinoic acid receptor oncoprotein. Cell. 1994;76:333–43.

    Article  PubMed  CAS  Google Scholar 

  20. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.

    Article  PubMed  CAS  Google Scholar 

  21. Quignon F, Chen Z, de Thé H. Retinoic acid and arsenic: towards oncogene targeted treatments of acute promyelocytic leukaemia. Biochim Biophys Acta. 1997;1333:M53–61.

    PubMed  CAS  Google Scholar 

  22. Huang M, Ye Y, Chen R, Chai J, Lu J, et al. Use of all trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood. 1988;72:567–72.

    PubMed  CAS  Google Scholar 

  23. Warrell R, de Thé H, Wang Z, Degos L. Acute promyelocytic leukemia. New Engl J Med. 1993;329:177–89.

    Article  PubMed  CAS  Google Scholar 

  24. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140–5.

    Article  PubMed  CAS  Google Scholar 

  25. Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood. 2001;97:73–80.

    Article  PubMed  CAS  Google Scholar 

  26. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O’Brien S, Kantarjian H, et al. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006;47:1062–8.

    Article  PubMed  CAS  Google Scholar 

  27. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, et al. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995;85:2643–53.

    PubMed  CAS  Google Scholar 

  28. Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene. 2001;20:7257–65.

    Article  PubMed  CAS  Google Scholar 

  29. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998;92:2244–51.

    PubMed  CAS  Google Scholar 

  30. Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins. Proc Natl Acad Sci USA. 1999;96:14807–12.

    Article  PubMed  CAS  Google Scholar 

  31. Chen G-Q, Zhu J, Shi X-G, Ni J-H, Zhong H-J, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–61.

    PubMed  CAS  Google Scholar 

  32. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.

    Article  PubMed  CAS  Google Scholar 

  33. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17:131–4.

    Article  PubMed  CAS  Google Scholar 

  34. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345–53.

    PubMed  CAS  Google Scholar 

  35. Lallemand-Breitenbach V, Guillemin M-C, Janin A, Daniel M-T, Degos L, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999;189:1043–52.

    Article  PubMed  CAS  Google Scholar 

  36. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA. 1997;94:3978–83.

    Article  PubMed  CAS  Google Scholar 

  37. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008;10:538–46.

    Google Scholar 

  38. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547–55.

    Article  PubMed  CAS  Google Scholar 

  39. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 2001;193:1361–72.

    Article  PubMed  CAS  Google Scholar 

  40. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA. 2000;97:10173–8.

    Article  PubMed  CAS  Google Scholar 

  41. Jing Y, Wang L, Xia L, Chen G, Chen Z, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001;97:264–9.

    Article  PubMed  CAS  Google Scholar 

  42. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101:5328–35.

    Article  PubMed  CAS  Google Scholar 

  43. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–73.

    Article  PubMed  CAS  Google Scholar 

  44. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106:3342–7.

    Google Scholar 

  45. Quenech’Du N, Ruchaud S, Khelef N, Guiso N, Lanotte M. A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. Leukemia. 1998;12:1829–33.

    Article  PubMed  Google Scholar 

  46. Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood. 2002;99:1014–22.

    Article  PubMed  CAS  Google Scholar 

  47. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, et al. In vivo activation of camp signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med. 2002;196:1373–80.

    Article  PubMed  CAS  Google Scholar 

  48. Duprez E, Lillehaug JR, Naoe T, Lanotte M. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. Oncogene. 1996;12:2451–9.

    PubMed  CAS  Google Scholar 

  49. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, et al. Rexinoid-triggered differentiation and tumours selective apoptosis of AML by protein kinase-A-mediated de-subordination of RXR. Cancer Res. 2005;65:8754–65.

    Article  PubMed  CAS  Google Scholar 

  50. Bruck N, Vitoux D, Ferry C, Duong V, Bauer A, et al. A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J. 2009;28:34–47.

    Article  PubMed  CAS  Google Scholar 

  51. Bour G, Gaillard E, Bruck N, Lalevee S, Plassat JL, et al. Cyclin H binding to the RARalpha activation function (AF)-2 domain directs phosphorylation of the AF-1 domain by cyclin-dependent kinase 7. Proc Natl Acad Sci USA. 2005;102:16608–13.

    Article  PubMed  CAS  Google Scholar 

  52. Gaillard E, Bruck N, Brelivet Y, Bour G, Lalevee S, et al. Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc Natl Acad Sci USA. 2006;103:9548–53.

    Article  PubMed  CAS  Google Scholar 

  53. Rochette-Egly C, Adam S, Rossignol M, Egly J-M, Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell. 1997;90:97–107.

    Article  PubMed  CAS  Google Scholar 

  54. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15:494–501.

    Article  PubMed  CAS  Google Scholar 

  55. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, et al. Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia. Blood. 2009;114:5415–25.

    Google Scholar 

  56. Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia. 2009;23:1462–71.

    Article  PubMed  CAS  Google Scholar 

  57. Du C, Redner RL, Cooke MP, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RAR alpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RAR alpha-fusion genes. Blood. 1999;94:793–802.

    PubMed  CAS  Google Scholar 

  58. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008;14:1333–42.

    Article  PubMed  CAS  Google Scholar 

  59. Licht JD. Acute promyelocytic leukemia—weapons of mass differentiation. N Engl J Med. 2009;360:928–30.

    Article  PubMed  CAS  Google Scholar 

  60. Kogan SC. Curing APL: differentiation or destruction? Cancer Cell. 2009;15:7–8.

    Article  PubMed  CAS  Google Scholar 

  61. Zheng X, Seshire A, Ruster B, Bug G, Beissert T, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica. 2007;92:323–31.

    Article  PubMed  CAS  Google Scholar 

  62. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995;85:1083–94.

    PubMed  CAS  Google Scholar 

  63. Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811–4.

    Article  PubMed  CAS  Google Scholar 

  64. He L-Z, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126–35.

    Article  PubMed  CAS  Google Scholar 

  65. Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815–8.

    Article  PubMed  CAS  Google Scholar 

  66. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, et al. Comprehensive genomic screens identify a role for PLZF-RAR{alpha} as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood. 2009;114:5499–511.

    Google Scholar 

  67. Cassinat B, Guillemot I, Molucon-Chabrot C, Zassadowski F, Fenaux P, et al. Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response. Haematologica. 2006;91:ECR58.

    PubMed  Google Scholar 

  68. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARalpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998;90:124–33.

    Article  PubMed  CAS  Google Scholar 

  69. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 2009;15:6321–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, American University of Beirut, Beirut, Lebanon

    Rihab Nasr

  2. Hôpital St. Louis, Service de Biochimie, Equipe labellisée Ligue Nationale Contre le Cancer, INSERM/CNRS/Université de Paris 7 UMR 944/7212, 1, Av. C. Vellefaux, 75475, Paris Cedex 10, France

    Hugues de Thé

Authors
  1. Rihab Nasr
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Hugues de Thé
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Hugues de Thé.

About this article

Cite this article

Nasr, R., de Thé, H. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol 91, 742–747 (2010). https://doi.org/10.1007/s12185-010-0582-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0582-0

Keywords